RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 89.6%

Neg 0% Neu 0% Pos 89.6%

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.